Send us a text

The landscape of medication to treat ER+, HER2 negative or low is changing rapidly as patients experience progression on CDK4/6 inhibitors and look for next steps.  Now that biomarker testing is more readily available (both tissue and liquid), there are more options particularly in the PI3 kinase pathway.  In this episode we will discuss biomarker testing, the PI3 kinase pathway, and an exciting new patient initiative, the PIK3CA Pathbreakers.